Indeed, ILC2-derived IL-33 promotes tumor formation and metastasis in breast cancer by upregulating Treg cells through inducible co-stimulator (ICOS)/ICOS ligand (ICOSL) interaction (121), whereas IL-33 also activates ILC2s to recruit eosinophils through ICOS/ICOSL interaction during lung inflammation (137). Here, IL33 is linked to breast carcinoma.